{
  "trial_id": "NCT03958656",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "SLAMF7 expression must be detected on malignant plasma cells from either bone marrow or a plasmacytoma by flow cytometry or immunohistochemistry.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Bone marrow plasma cells must make up less than or equal to 50% of total bone marrow cells based on a bone marrow biopsy performed within 24 days of the start of protocol treatment.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have received at least 3 different prior treatment regimens for multiple myeloma",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Must have prior exposure to an immunomodulatory drug (IMiD) such as lenalidomide and a proteasome inhibitor",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients must have measurable MM as defined by at least one of the criteria below.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Seronegative for HIV antibody.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A patient with a negative blood PCR test for hepatitis B DNA test can be enrolled. If hepatitis B DNA (PCR) testing is not available, patients with a negative hepatitis B surface antigen and negative hepatitis B core antibody can be enrolled.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients must be tested for the presence of Hepatitis C antigen by PCR and be HCV RNA negative in order to be eligible. Only if Hepatitis C PCR testing is not available in a timely manner, patients who are Hepatitis C antibody-negative can be enrolled.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Greater than or equal to 18 years of age and less than or equal to age 73.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Able to understand and sign the Informed Consent Document.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Clinical performance status of ECOG 0-2",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients of both sexes must be willing to practice birth control from the time of enrollment on this study and for four months after last day of receiving protocol treatment.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients who are receiving any other investigational agents.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient has a history of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT03958656",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}